Mylan Pharmaceuticals, a subsidiary of Mylan Inc, has started marketing 1% Clindamycin and 5% Benzoyl Peroxide Gel based on an agreement with licensing partner Dow Pharmaceutical Sciences, a
Nycomed and Forest Laboratories have announced results of four phase III trials published in The Lancet. Result showed that roflumilast, a phosphodiesterase 4 (PDE4) inhibitor, improved lung function
A study published by the scientists from UC Santa Barbara, claims of discovering a new drug delivery system. The new system is said to be a biological mechanism
CellaVision is adapting its current range of products for use in veterinary laboratories. Several veterinary laboratories are evaluating CellaVision’s products in Sweden and the US. The results are
Bristol-Myers Squibb has reported that the initial tender offer for all outstanding shares of common stock of Medarex has expired on August 26, 2009, and was not extended.
Biolex Therapeutics has entered into an agreement with Cook Pharmica under which Cook will manufacture drug substance for use in Biolex’s planned phase 3 clinical trials of Locteron.
Arno Therapeutics (Arno) has reported the first patient dosing in a phase I clinical study of AR-12 (OSU-03012) in adult patients with advanced or recurrent solid tumors or
PolyMedix and the University of Massachusetts have received a $100,000 phase I Small Business Technology Transfer (STTR) contract. The contract will support research to identify lead antimicrobial compounds
Neuland Laboratories (Neuland) has initiated manufacturing of peptides blocks by commercializing the production of Fmoc Pseudoproline Dipeptides and other building blocks in India and the US subsidiary. The
Warnex has reported that its Medical Laboratories division has launched a test for the detection of a mutation of the pandemic influenza A H1N1 virus, which is associated
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.